Literature DB >> 27339087

Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer.

Feifei Luo1,2, Jiawen Qian2, Jiao Yang2, Yuting Deng2, Xiujuan Zheng2, Jie Liu1,2, Yiwei Chu1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27339087      PMCID： PMC5129888          DOI： 10.1038/cr.2016.81

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


× No keyword cloud information.
  12 in total

Review 1.  Bispecific T-cell engagers for cancer immunotherapy.

Authors:  Amelia M Huehls; Tiffany A Coupet; Charles L Sentman
Journal:  Immunol Cell Biol       Date:  2014-11-04       Impact factor: 5.126

2.  The quest for spatio-temporal control of CAR T cells.

Authors:  Jie Sun; Michel Sadelain
Journal:  Cell Res       Date:  2015-11-17       Impact factor: 25.617

3.  Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.

Authors:  Liping L Sun; Diego Ellerman; Mary Mathieu; Maria Hristopoulos; Xiaocheng Chen; Yijin Li; Xiaojie Yan; Robyn Clark; Arthur Reyes; Eric Stefanich; Elaine Mai; Judy Young; Clarissa Johnson; Mahrukh Huseni; Xinhua Wang; Yvonne Chen; Peiyin Wang; Hong Wang; Noel Dybdal; Yu-Waye Chu; Nicholas Chiorazzi; Justin M Scheer; Teemu Junttila; Klara Totpal; Mark S Dennis; Allen J Ebens
Journal:  Sci Transl Med       Date:  2015-05-13       Impact factor: 17.956

4.  Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.

Authors:  Renier Brentjens; Raymond Yeh; Yvette Bernal; Isabelle Riviere; Michel Sadelain
Journal:  Mol Ther       Date:  2010-04       Impact factor: 11.454

Review 5.  Blinatumomab: first global approval.

Authors:  Mark Sanford
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

Review 6.  Bispecific antibodies engage T cells for antitumor immunotherapy.

Authors:  Bryan D Choi; Mingqing Cai; Darell D Bigner; Ankit I Mehta; Chien-Tsun Kuan; John H Sampson
Journal:  Expert Opin Biol Ther       Date:  2011-03-30       Impact factor: 4.388

7.  Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.

Authors:  Bryan D Choi; Chien-Tsun Kuan; Mingqing Cai; Gary E Archer; Duane A Mitchell; Patrick C Gedeon; Luis Sanchez-Perez; Ira Pastan; Darell D Bigner; John H Sampson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

8.  Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.

Authors:  Ralf Bargou; Eugen Leo; Gerhard Zugmaier; Matthias Klinger; Mariele Goebeler; Stefan Knop; Richard Noppeney; Andreas Viardot; Georg Hess; Martin Schuler; Hermann Einsele; Christian Brandl; Andreas Wolf; Petra Kirchinger; Petra Klappers; Margit Schmidt; Gert Riethmüller; Carsten Reinhardt; Patrick A Baeuerle; Peter Kufer
Journal:  Science       Date:  2008-08-15       Impact factor: 47.728

Review 9.  Blinatumomab: a historical perspective.

Authors:  Dirk Nagorsen; Peter Kufer; Patrick A Baeuerle; Ralf Bargou
Journal:  Pharmacol Ther       Date:  2012-08-24       Impact factor: 12.310

Review 10.  Chimeric antigen receptor therapy for cancer.

Authors:  David M Barrett; Nathan Singh; David L Porter; Stephan A Grupp; Carl H June
Journal:  Annu Rev Med       Date:  2013-11-20       Impact factor: 13.739
View more
  7 in total

1.  Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor.

Authors:  Yuedi Wang; Yiyuan Gao; Congyi Niu; Bo Wang; Shushu Zhao; Gils Roex; Jiawen Qian; Jingbo Qie; Lin Chen; Chenhe Yi; Sébastien Anguille; Jie Liu; Feifei Luo; Yiwei Chu
Journal:  Cancer Immunol Immunother       Date:  2022-04-19       Impact factor: 6.630

Review 2.  Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.

Authors:  Hamid R Mirzaei; Analiz Rodriguez; Jennifer Shepphird; Christine E Brown; Behnam Badie
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

Review 3.  New Chimeric Antigen Receptor Design for Solid Tumors.

Authors:  Yuedi Wang; Feifei Luo; Jiao Yang; Chujun Zhao; Yiwei Chu
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

Review 4.  Chimeric antigen receptor T cells: a novel therapy for solid tumors.

Authors:  Shengnan Yu; Anping Li; Qian Liu; Tengfei Li; Xun Yuan; Xinwei Han; Kongming Wu
Journal:  J Hematol Oncol       Date:  2017-03-29       Impact factor: 17.388

Review 5.  Immunotherapy for Gastric Cancer: Time for a Personalized Approach?

Authors:  Riccardo Dolcetti; Valli De Re; Vincenzo Canzonieri
Journal:  Int J Mol Sci       Date:  2018-05-29       Impact factor: 5.923

Review 6.  Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies.

Authors:  Yan Dong; Zhuo Wan; Xiaotong Gao; Guodong Yang; Li Liu
Journal:  Front Immunol       Date:  2021-04-21       Impact factor: 7.561

Review 7.  From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer.

Authors:  Jiangang Sun; Xiaojing Li; Peng Chen; Yongshun Gao
Journal:  J Inflamm Res       Date:  2022-07-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.